JNJ - How I Pick Approved Needles in a Vaccine Haystack
In the last few weeks, bio-tech companies of all sizes have made impressive strides toward a vaccine. Many dozens of approaches are being taken, most will fail. With a future potential coronavirus inoculation carrying such an overwhelmingly positive public utility, which company will win?
Choosing from the companies racing to the finish line is quite difficult, and also risky. Moderna (NASDAQ: MRNA) reported robust preliminary news of Phase I trials recently that sent shares soaring. Immediately speculation rose on the extensiveness of the data release, sending shares plummeting just one day later.
Getty Images